Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

« Older Entries
Newer Entries »

Tetra Bio-Pharma $TBP.ca Opens the Market $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:31 PM on Wednesday, December 6th, 2017

Logo tetrabiopharma rgb web

  • Bernard Fortier, CEO, Tetra Bio-Pharma Inc. (TBP), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market

TORONTO, Dec. 5, 2017 – Bernard Fortier, CEO, Tetra Bio-Pharma Inc. (TBP), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market. Tetra Bio-Pharma biopharmaceutical company that is engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements. Tetra Bio-Pharma Inc. commenced trading on TSX Venture Exchange on August 16, 2017.

SOURCE TMX Group Limited

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Opens the Market $AERO $CBDS $CGRW $APH.ca $GBLX

Aphria $APH.ca to supply medical marijuana to Shoppers Drug Mart $N.ca $TBP.ca $MCOA

Posted by AGORACOM-JC at 1:19 PM on Tuesday, December 5th, 2017
  • Aphria Inc struck a deal to sell medical marijuana to Shoppers Drug Mart, Canada’s largest pharmacy chain
  • “Subject to Health Canada’s approval of Shoppers Drug Mart’s application to be a licensed producer, under the terms of the agreement the Company will supply Shoppers Drug Mart with Aphria-branded medical cannabis products,” a release from Aphria said. “It is expected the products will be sold online, as Canadian regulations currently restrict the sale of medical cannabis in retail pharmacies.”

Shoppers, or its parent company, Loblaw Companies Ltd., have not been issued a licence to dispense cannabis yet, according to Health Canada’s list of companies registered to grow and sell medical marijuana. It was reported in November that Shoppers was searching for someone to serve as the pharmacy chain’s medical marijuana brand manager.

Vic Neufeld, chief executive of of Aphria, said his company had a five-year agreement with Shoppers as its “first and primary supplier,” and that every year of the deal included “minimum requirements on volumes that they must purchase from us for them to maintain the following year’s exclusivity.”

Based on the terms of the agreement, specific financial terms would not be disclosed, he said.

“This stems from our long-held belief that pharmacies can, and should, play an important role in the safe and secure distribution of medical cannabis in Canada,” Neufeld added on a conference call with analysts. “It gives Aphria a huge, huge lift when it comes to the shareholder value.”

Trading of Aphria shares was halted Monday afternoon, with the company’s stock price closing up 1.93 per cent, at $11.62. Shares of the greenhouse grower are up nearly 86 per cent for the year.

The supply agreement between Aphria and Shoppers has been reached approximately seven months out from Canada’s July 2018 target date for the legalization of recreational cannabis. It also follows Saskatchewan-based medical marijuana company CanniMed Therapeutics Inc. becoming the first licensed producer to sign a deal with a national pharmacy chain when it signed a letter of intent with PharmaChoice in March of this year.

Neufeld said that during the “many months” of conversations with Shoppers, they had only discussed medical marijuana sales, not recreational.

Neufeld also said the form of “exclusivity” Aphria had given Shoppers does not restrict the pharmacy from considering “other forms of intake products, medical devices by way of example.”

“However, there is an understanding that should we be able to service their needs we would be given an opportunity to bid on it,” Neufeld added.

According to Aphria’s most recent results, for the quarter ended Aug. 31, the company reported net income of $15 million and a 15 per cent increase in sales, to 852 kilograms or kilograms equivalent of cannabis.

“For a period of time, we will not engage in any other conversations or business transactions with other national pharmacy banners in excess of a certain size,” Neufeld said. “Have we excluded certain banners? Yes, however, for us it was very important to get Canada’s leading banner in alignment with the Aphria business model, and so that’s what we agreed to.”

[email protected]
Twitter: @geoffzochodne

Source: http://business.financialpost.com/commodities/ontario-cannabis-company-aphria-to-supply-medical-marijuana-to-shoppers-drug-mart

Tags: , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on Aphria $APH.ca to supply medical marijuana to Shoppers Drug Mart $N.ca $TBP.ca $MCOA

Namaste $N.ca Announces Non-Binding Letter of Intent With O Cannabis Clinic for Management Services $ATT.ca $ABCN.ca $ACG.ca $ACB

Posted by AGORACOM-JC at 8:44 AM on Tuesday, December 5th, 2017

Nlogo

  • LOI represents a major milestone for Namaste in the expansion of its platform into medical cannabis sales using the Company’s innovative telemedicine application, and will provide an incredibly efficient platform for patient consultations and medical documentation issuance

VANCOUVER, British Columbia, Dec. 05, 2017 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (OTCQB:NXTTF) (FRANKFURT:M5BQ) is pleased to announce that it has signed an non-binding letter of intent (“LOI”)  with O Cannabis We Stand On Guard For Thee (“O Cannabis”) under which O Cannabis will provide patient consultation services to Namaste’s wholly owned subsidiary, NamasteMD Inc. (“NamasteMD”). Pursuant to the LOI, O Cannabis will provide management services to NamasteMD that will include patient consultations, education, strain recommendations and medical document issuance to qualified patients under the guidance of nurse practitioners. In addition to these services, O Cannabis will also be offering a select range of Namaste’s vaporizer hardware in their online platform.

This LOI represents a major milestone for Namaste in the expansion of its platform into medical cannabis sales using the Company’s innovative telemedicine application, and will provide an incredibly efficient platform for patient consultations and medical documentation issuance. NamasteMD customers will have the ability to connect to Namaste’s e-commerce platform through Namaste’s wholly owned subsidiary, Cannmart Inc. (“CannMart”), which will provide patients with an online marketplace for medical cannabis products, including strains sourced from both domestic and international licensed producers. CannMart is a late stage applicant for a “Sales Only License” under the Canadian Access to Cannabis for Medical Purposes Regulations (“ACMPR”) program. Namaste’s goal is to become Canada’s leading medical cannabis online retailer by leveraging its existing consumer base, along with utilizing its advanced expertise in e-commerce. In doing so, Namaste believes it can successfully convert and on-board patients at an accelerated growth rate and offer the best quality of care for its patients. Namaste believes that with its aggressive growth strategy and the implementation of NamasteMD, it will be able to accumulate a minimum of 18,200 patients within the first calendar year of operations. This figure is based on Namaste’s current site traffic of 1,000 unique visitors per day with a 5% conversion rate, which would generate 350 patients per week. Namaste expects each patient acquisition to cost on average $60 per patient, based on the terms of the LOI, which is currently lower than any industry standard for medical patients.

About O Cannabis
O Cannabis offers affordable medical cannabis telemedicine appointments to patients across Canada, allowing timely access to quality medicine in remote and under-serviced regions; from Yukon to Newfoundland and everywhere in between. O Cannabis has built a name for themselves by offering unparalleled patient education and industry leading follow up care. O Cannabis patients report their appreciation for the easy and fun telemedicine experience, O Cannabis’ streamlined approach to medical document issuance and the exceptional care patients receive at each step of their medical cannabis journey.

Terms of the LOI
Under the terms of the LOI, the O Cannabis management team will be responsible for the general operation of NamasteMD’s platform and will provide the following services:

  • Patient Qualification
  • Patient Onboarding
  • Education
  • Recommendations (strains and dosages)
  • Follow-up Care
  • Medical Documents
  • Self-titration Training
  • Maintaining 75% patient retention rates

In return for these services, Namaste will pay O Cannabis as follows:

  • CAD $60 for each patient approval, being a patient consultation resulting in the issuance of a prescription for medical cannabis
  • 50% of the net profit for “platinum” packages, as will be outlined in the definitive agreement
  • 5% of the gross revenue collected for patients where medical cannabis is sourced from local licensed producers
  • 10% of the gross revenue collected for patients where medical cannabis is sourced from international licensed producers
  • 15% of the gross revenue collected through the sale of Namaste’s vaporizers and cannabis ancillary products, which O Cannabis will add to its website
  • The issuance of 15,000 common share stock options to the O Cannabis management team

Closing of the proposed definitive agreement will be contingent on negotiation and execution of definitive documentation containing standard terms, representations and warranties and indemnities for an agreement of this nature, approval of the agreement by each party’s respective board of directors and shareholders, if applicable, and by the Canadian Securities Exchange, if applicable.

NamasteMD is an innovative application that connects patients with medical practitioners through a secure video conference call and incorporates industry-leading facial recognition technology, including instant age and identity verification using data feeds linked to federal databases.  The O Cannabis management team is a highly trained group of medical professionals that offer industry leading care for their patients. Through the NamasteMD platform, patients will be offered a variety of packages that will include both free and paid options. Once a patient receives a medical document, they will have access to purchase directly from CannMart’s medical cannabis marketplace. The Company expects full launch of NamasteMD, including the app for both Apple and Android platforms, to be in operation and accepting patients as soon as December 15, 2017.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “With many of these exciting initiatives now in place, Namaste believes it has successfully created the necessary infrastructure to become a leader in medical cannabis sales in Canada. In addition to Canada, Namaste believes this infrastructure can be easily implemented into other progressive jurisdictions where medical cannabis legislation is in place, and fully intends on exploiting all markets where Namaste has existing operations and market presence. Our goal now is to focus heavily on patient acquisition through our existing database of consumers and to accelerate growth through our e-commerce platform.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:
www.namastetechnologies.com
www.namastevaporizers.com
www.namastevaporizers.co.uk
www.everyonedoesit.com
www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

(more…)

Tags: , ,
Posted in Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces Non-Binding Letter of Intent With O Cannabis Clinic for Management Services $ATT.ca $ABCN.ca $ACG.ca $ACB

Canadian #Marijuana awards show lights up with first-ever gala #MMJ $TBP.ca $N.ca $MCOA

Posted by AGORACOM-JC at 10:48 AM on Thursday, November 30th, 2017
  • You know marijuana is going mainstream when the list of attendees who reserved tables reads like a who’s who of Canada’s haze of law and accounting firms, including Torys LLP, Dentons, Cassels Brock & Blackwell LLP, Bennett Jones LLP, investment dealer Eight Capital and accounting giants KPMG and MNP
By Lisa WrightBusiness Reporter
Wed., Nov. 29, 2017

What do you do if you’re a budding awards show trying to create a buzz around Canada’s $8.7-billion cannabis market?

First you weed out the best producers from the very large crop of products out there. Then you book a swanky joint and roll out the red carpet for business types looking to get in on the potential pot of gold surrounding legalization next summer.

The CEO of Lift Co., the online marketplace for the medical marijuana industry that is holding the event, says it was high time for a grass gala to highlight the fourth annual Canadian Cannabis Awards – previously held only online – in an effort to add some legitimacy to the often stigmatized cannabis community.

“It’s really going to be a mini Oscars” of pot, said Matei Olaru of the awards show being held Thursday night at the historic Carlu at College Park.

You know marijuana is going mainstream when the list of attendees who reserved tables reads like a who’s who of Canada’s haze of law and accounting firms, including Torys LLP, Dentons, Cassels Brock & Blackwell LLP, Bennett Jones LLP, investment dealer Eight Capital and accounting giants KPMG and MNP.

“These are recognizable names excited to be associated publicly with the industry,” said Olaru.

“The industry has matured enough and there are enough players, so it’s the right time for this,” he added.

In fact they will hand out a whopping 75 awards to producers and numerous other players in the marijuana business during an evening of cocktails and plenty of munchies over a sit-down dinner. The laughs will officially be provided by famed comedian twins The Lucas Brothers of 22 Jump Street and Netflix fame, who will be performing standup before the after party.

Categories range from the traditional — employer of the year, startup of the year, innovator of the year, deal of the year and even lifetime achievement award — to the offbeat, including the best in show of vape lounges, cannabis chefs, desktop and portable vaporizers, top testing lab and best home growing box.

“It’s a way to showcase those achievements,” said Olaru, whose mission is to demystify the continued confusion around the medical marijuana market as it grows like a weed.

For instance pot smoking rapper Snoop Dogg recently partnered with Canadian licensed producer Tweed, which is nominated in multiple categories.

Another sign that legalization is around the corner is Lift landing official support this week from MADD Canada as it develops Canada’s first retail training certification program for frontline staff at cannabis retailers who will have legal storefronts as of July 2018.

“Our experience with alcohol sales has shown that having comprehensive training and responsible service guidelines for front-line staff is crucial to reducing alcohol-related harms, including impaired driving,” says MADD Canada chief executive officer Andrew Murie.

“The same will be true of cannabis retail sales. MADD Canada is pleased to partner with a leader like Lift and support this program, which will ensure that all those involved in the retail sales of cannabis are well-trained about the products, about safe usage guidelines and about social responsibility principles,” he said in a release.

Source: https://www.thestar.com/business/2017/11/29/canadian-marijuana-awards-show-lights-up-with-first-ever-gala.html

Tags: , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on Canadian #Marijuana awards show lights up with first-ever gala #MMJ $TBP.ca $N.ca $MCOA

Marijuana Company of America $MCOA Partners with #HoneyB Healthy Living to Launch the #Benihemp Brand $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:54 AM on Thursday, November 30th, 2017

15233 mcoa

  • Announced that it has partnered with the founders of HoneyB Healthy Living to develop Convenient Hemp Mart, LLC’s “BeniHemp” branded products
  • Targeting convenience stores for CBD product distribution. MCOA has invested $100,000 into the start-up project for a 25% equity stake.

Escondido, California–(November 30, 2017) – MARIJUANA COMPANY OF AMERICA INC. (OTC: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis company, is pleased to announce that it has partnered with the founders of HoneyB Healthy Living to develop Convenient Hemp Mart, LLC’s “BeniHemp” branded products targeting convenience stores for CBD product distribution. MCOA has invested $100,000 into the start-up project for a 25% equity stake.

BeniHemp products includes topicals, tinctures and edibles conveniently packaged in 1-day, 2-day and 30-day supplies. The target markets are convenience stores, smoke shops, gas stations and similar types of small retail businesses where CBD commerce has significant potential to generate sales from the impulse buyer at the register.

Convenient Hemp Mart is in the process of developing unique sample sized packaging for consumers to try its BeniHemp products. When customers have a positive experience with BeniHemp sample products, they will then be able to purchase a monthly supply and sign up for auto ship online. Store owners will continue to generate additional revenue without the burden of managing inventory and shelf space.

MCOA Chief Executive Officer Donald Steinberg observed: “The BeniHemp model is attractive to convenience store operators, who understand the value of selling sample sized packages of CBD products that will ultimately generate online sales for monthly orders where they can generate revenues from sales they never see or have to manage. We believe this is an attractive model for small retail business owners looking for every opportunity to tap into the rapidly emerging CBD market to generate additional revenue. We have high expectations for what the experienced HoneyB team can accomplish.”

HoneyB Healthy Living and Convenient Hemp Mart are working with MCOA and Space Cowboys, Inc. in Loveland and Longmont Colorado to establish a secure and consistent supply of quality cannabinoids to fulfill demand for current and future product development and distribution.

The expectation is that BeniHemp will soft launch in December 2017 with the full launch in January 2018. The BeniHemp website is in development and will be launched in January as well. Benihemp products have already been manufactured are pending shipment once the package designs, including counter top displays, floor displays and related marketing materials are complete.

Frank Phillips, Conveniant Hemp Mart’s Chief Executive Officer commented: “We are extremely excited to come to market with the very highest quality products designed specifically for curious first-time cannabinoid users. The CBD market is experiencing exponential growth and we intend to capture market share in one of the highest trafficked marketplaces, convenience stores. Because of the expertise of Space Cowboys in producing some of the highest quality hemp oil on the market, and the proven manufacturing and formulation abilities of our Honey B Healthy Living team, we believe that our introductory products coming to convenience store shelves will generate considerable traffic to our online portals for monthly order placements creating an absolute win for the stores carrying our products.”

About Marijuana Company of America, Inc.
MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
[email protected]

Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America $MCOA Partners with #HoneyB Healthy Living to Launch the #Benihemp Brand $AERO $CBDS $CGRW $APH.ca $GBLX

AGORACOM INTERVIEW: Why Namaste $N.ca Divested Its’ US Assets and Why It Is Now The Amazon “Plus” Of The #Marijuana Space $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 7:45 AM on Thursday, November 30th, 2017

Namaste released news yesterday morning that it was divesting of its’ US operations.  The move would clear hurdles around major partnerships, financing and uplisting created by the political uncertainty surrounding the legalization of cannabis in the US.  Following the company’s conference call this morning, AGORACOM sat down with CEO Sean Dollinger to discuss the major advantages and opportunities that would arise as a result of divesting US operations, including:

    • Partnership discussions with Licensed Producers (LPs)
    • Investments by LPs
    • Attracting large institutional investors
    • Listing on the TSX Venture Exchange

We then switched our focus to current operations and upcoming events, including:

  • A 500% increase in Black Friday /  Cyber Monday sales
  • The imminent approval of its’ CannMart Medical Marijuana License
  • NamasteMD launch on December 11
  • Why Namaste is now the Amazon Of The Marijuana Space
  • Why investors need to understand the long-term picture and stop looking at the tape

 

Tags: , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on AGORACOM INTERVIEW: Why Namaste $N.ca Divested Its’ US Assets and Why It Is Now The Amazon “Plus” Of The #Marijuana Space $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma $TBP.ca accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet Ahead of Schedule in the US $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 5:29 PM on Tuesday, November 28th, 2017

Logo tetrabiopharma rgb web

  • Announced that it is partnering with a major manufacturer of controlled active pharmaceutical ingredients (APIs) in the USA for the manufacturing of Dronabinol XL AdVersa® 
  • Company accelerates its plans to submit a 505(b)(2) New Drug Application for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS

OTTAWA, ONTARIO–(Nov. 28, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it is partnering with a major manufacturer of controlled active pharmaceutical ingredients (APIs) in the USA for the manufacturing of Dronabinol XL AdVersa® as the Company accelerates its plans to submit a 505(b)(2) New Drug Application (NDA) for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS.

According to market research by the International Agency for Research on Cancer 2, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US$1.88 bn by 2020, rising from its 2013 valuation of US$1.28 bn. Based on the expected improved safety profile of a delayed release Dronabinol, Tetra expects that the Adversa® tablet can gain an important share of this market within three (3) years of its launch in the USA, with sales of Adversa® that could potentially reach $30,000,000 USD at the end of the third year of sales.

In March 2017, Tetra licensed the Dronabinol XL AdVersa® technology from IntelGenx and entered into a co-development agreement to bring this controlled release formulation of Dronabinol (tetrahydrocannabinol; THC) to the market. Tetra is looking to accelerate its commercialization plans in the USA by seeking marketing approval by the Food and Drug Administration (FDA) for the following therapeutic indications, which are identical to those of Marinol® (dronabinol capsules): “Use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.” It’s buccal administration in cases of nausea makes it an attractive therapeutic option for cancer patients.

Tetra’s partnership with a major manufacturer in the USA that has been manufacturing dronabinol for years to develop the commercial manufacturing of this innovative patent-protected new drug is key in its submission to the FDA. The submission of an NDA under 505(b)(2) to the U.S. Food and Drug Administration (FDA) requires demonstration that the new controlled release formulation provides similar systemic exposure to the listed/approved drug dronabinol. The data generated by IntelGenx demonstrated that the new formulation increases bioavailability of the THC and the new route of administration results in a lower level of the metabolite 11-hydroxy THC. The implications are that a lower dose of THC will be required. The Dronabinol XL AdVersa® formulation is absorbed by the buccal mucosa thereby limiting exposure to the gastrointestinal tract. These differentiating points, along with other characteristics of the new drug Dronabinol XL AdVersa®, are expected to result in a diminution of the side effects traditionally described with dronabinol capsules thus in a more optimal product for patients.

In 2018, Tetra will perform a comparative pharmacokinetic study of Dronabinol XL AdVersa® versus the listed drug. This study, along with the manufacturing file, will be part of the basis for the Tetra’s planned 505(b)(2) new drug application. The Company expects to complete the analysis of the trial data and announce results in the fourth quarter of 2018, followed by a potential NDA submission in 2019 and will request classification under Schedule III of the Schedules of Controlled Substances.

Dr. Guy Chamberland commented that “in parallel to the preparation of the NDA file, Tetra and IntelGenx will continue the development of PPP002 (Dronabinol XL AdVersa®) as an adjunct therapy for opioid sparing in chronic cancer pain. The commercialization of Dronabinol XL AdVersa® will allow the co-development team to focus its attention on the clinical development activities in opioid sparing. Once completed these Phase III clinical trials will allow Tetra to submit supplements to the NDA and expand the indications of drug approval.”

1: Completion of NDA file expected late 2018/early 2019 followed by a 505(b)(2) NDA submission 1 year ahead of original plans.

2: https://www.transparencymarketresearch.com/cinv-market.html

Market Info CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)2:

According to market research by the International Agency for Research on Cancer (IARC), in 2012, there were 14 million new cases of cancer diagnosed and approximately 4 million people per year receiving chemotherapy globally. CINV affects nearly 70-80% of patients undergoing chemotherapy.

505(b)(2) New Drug Application:

The 505(b)(2) application is one of three established types of new drug application (NDA). It is defined in The Federal Food Drug and Cosmetics Act (FDC Act) as an NDA containing investigations of safety and effectiveness that are being relied upon for approval and were not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. These applications rely in part on the FDA’s findings of safety and/or effectiveness for a previously approved drug (Marinol®(Dronabinol capsules)).

The 505(b)(2) NDA also differs from an abbreviated NDA (ANDA) for generic drugs (Section 505(j) of the FDC Act). An ANDA is an application containing information to demonstrate that the new product is identical to a previously approved product.

About IntelGenx:

IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.

About PPP002 /Dronabinol XL AdVersa®:

PPP002 /Dronabinol XL AdVersa® is a sustained release formula of THC in the form of a buccally absorbed tablet.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Correction to Tetra Bio-Pharma’s previous press release announcing Stock Options Grants

Company also wishes to announce a correction to the information disclosed in its press release dated October 4th, 2017 regarding the grant of an aggregate of 1,400,000 incentive stock options to certain members of its board of directors (“Board of Directors“) and executive officers on October 3rd, 2017. Contrary to what was disclosed in such press release, such grant was not finalized due to a corporate deficiency related to the Board of Directors’ approval.

On November 27, 2017, such deficiency was corrected and, in accordance with the Company’s stock option plan and subject to the approval of the Canadian Securities Exchange, the Board of Directors granted an aggregate of 1,400,000 incentive stock options (“options“) to certain directors, officers and consultants. Each option, vesting immediately upon grant or vesting once certain pre-determined milestones are met, as applicable, entitles the holder thereof to purchase one common share in the capital of the Company at a price of $0.71 per share until November 28, 2018 or November 28, 2021, as applicable.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Dronabinol XL AdVersa® product offering; guidance on expected sales volumes associated with the Dronabinol XL AdVersa® product offering; approval by the FDA of the Dronabinol XL AdVersa® clinical trial, competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tags: , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet Ahead of Schedule in the US $AERO $CBDS $CGRW $APH.ca $GBLX

Deal-Making in the #Cannabis Industry Hits an All-Time High: What It Means for #Marijuana Stocks $TBP.ca $N.ca $MCOA $ATT.ca $ABCN.ca $ACG.ca $ACB

Posted by AGORACOM-JC at 10:12 AM on Monday, November 27th, 2017

Could more deals mean more dollars for marijuana stock investors?

  • If it seems like there’s been a spurt of deals and potential deals going on in the cannabis industry lately, it’s because that’s exactly what’s happening.
Keith Speights
Nov 27, 2017 at 9:16AM

Canopy Growth Corporation (NASDAQOTH:TWMJF) scored what was probably the most highly publicized deal with large beverage company Constellation Brands (NYSE:STZ) buying a 9.9% stake in the Canadian marijuana grower for $245 million. But Canopy has also forged other agreements with smaller companies both before and after the Constellation partnership.

More recently, Aurora Cannabis (NASDAQOTH:ACBFF) launched a takeover bid for CanniMed Therapeutics. Aurora had wanted CanniMed’s board of directors to agree to an acquisition proposal made last week. When the board failed to respond, Aurora moved forward with its unsolicited takeover attempt.

Major deal-making in the cannabis industry is hitting an all-time high. Here are three ways it impacts not just the parties involved but marijuana stocks in general.

Image source: Getty Images.

1. Acceptance of the cannabis industry

While it’s true that more people have accepted legalization of both medical and recreational marijuana than ever before, the cannabis industry hasn’t entirely been viewed as part of the mainstream economy in the past. I think Constellation Brands’ partnership with and investment in Canopy Growth changes that significantly.

Constellation Brands isn’t a small fish in the pond. The company is a member of the S&P 500 and has a market cap of $43 billion. Its decision to partner with Canopy Growth amounted to an endorsement of the cannabis industry — at least in Canada. However, Constellation’s move could also lead to greater acceptance of the cannabis industry in the U.S.

The company’s CEO, Rob Sands, said in an interview with The Wall Street Journal, that Constellation thinks that legalization of recreational marijuana in the U.S. is “highly likely, given what’s happened at the state level.” Although Constellation Brands is echoing the stance taken by Canopy Growth of only selling marijuana in markets where it’s legal at a federal level, the prospects of future legalization throughout the U.S. can only be helped by a major company like Constellation making a big investment in a marijuana grower.

2. Acceleration of more deal-making

There have been plenty of deals that haven’t received quite as much attention as Constellation’s investment in Canopy Growth and Aurora Cannabis’ takeover attempt of CanniMed. For example, Canopy Growth recently acquired small Canadian medical marijuana grower TerrAscend. Earlier this month, Aurora increased its stake in Hempco Food and Fiber to more than 50%.

Image source: Getty Images.

There’s something of a “me, too” factor when mergers and acquisitions activity picks up. Companies that haven’t been making big deals can be spurred to action in fear of missing out.

Canopy Growth is currently the biggest marijuana grower in Canada. I have no doubt that its size made a difference in Constellation Brands choosing Canopy Growth as a partner. But Aurora Cannabis could become the largest marijuana grower (at least in terms of market cap) if its attempt to buy CanniMed is successful.

Just imagine what’s going through the minds of the executives running other major marijuana growers in Canada. If you’re the CEO of MedReleaf (NASDAQOTH:MEDFF) or Aphria (NASDAQOTH:APHQF), you have to at least be thinking about making some deals of your own.

In fact, MedReleaf recently announced a stock offering that will generate $100.5 million. What will this money be used for? The company intends “to finance the acquisition and/or construction of additional cannabis production and manufacturing facilities in Canada as well as in other jurisdictions with federal legal cannabis markets.” In other words, expect an acceleration of deal-making in the cannabis industry.

3. Attraction of more investors

My view is that deal-making in any industry attracts more investors to stocks in that industry. I see it happen frequently in the bopharmaceutical world, where the possibility of mergers and buyouts tends to bring some individual investors off the sidelines. I suspect that’s what is happening already and will only pick up in the months ahead.

There are several factors that could contribute to this. Size matters for many investors who are leery of putting their money into companies that are small. Deals also make headlines, and therefore bring the involved stocks to the attention of more investors.

Another key reason why I suspect the recent deals for marijuana stocks could attract more investors is the bandwagon effect. That’s especially applicable with Constellation Brands’ investment in Canopy Growth. Some individual investors are likely to think, “If a big company like Constellation thinks it’s a good investment, it probably is a good investment.” I’m not saying that line of thinking is necessarily correct, but I’d bet plenty of people have similar thoughts.

Adding it all up

So what does all of this mean for marijuana stocks in general? It should be good news.

Smaller companies could find themselves takeover targets of somewhat larger companies, just like the situation with CanniMed and Aurora Cannabis. Relatively larger companies like Aurora, Aphria, and MedReleaf could attract the attention of other alcoholic beverage makers not wanting to be left behind by Constellation Brands in a potential cannabis-infused beer market.

I think these and other Canadian marijuana stocks should go higher in the coming months. This won’t be driven entirely by mergers and acquisitions, though. Legalization of recreational marijuana in Canada in 2018 will be the biggest catalyst.

At the same time, investors shouldn’t throw out all the traditional rules of investing in stocks. Look at the underlying businesses, growth prospects, and valuations before investing in any stock. After all, the most important deal is the one that requires you to put your own hard-earned money at stake.

Tom Gardner: Forget Aurora Cannabis Inc.! This buying opportunity is bigger than I ever imagined…

A few months ago, Motley Fool CEO Tom Gardner recently discovered what he considers the greatest buying opportunity he’s seen in more than a decade… within a group of stocks no one is talking about. On Monday, November 27, at 9:30 A.M. ET, Tom is making an important announcement where he will discuss this buying opportunity and how it potentially impacts any investor in the market today. To learn how to access Tom’s timely update, click the button below.

Source: https://www.fool.com/investing/2017/11/27/deal-making-in-the-cannabis-industry-hits-an-all-t.aspx

Tags: , , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on Deal-Making in the #Cannabis Industry Hits an All-Time High: What It Means for #Marijuana Stocks $TBP.ca $N.ca $MCOA $ATT.ca $ABCN.ca $ACG.ca $ACB

Tetra Bio-Pharma’s $TBP.ca Business Model and Commercialization Strategy In Line with the Canadian Government’s Proposed Approach to the Regulation of Cannabis $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 5:08 PM on Wednesday, November 22nd, 2017

Logo tetrabiopharma rgb web

  • Canadian Government’s Proposed Approach to the Regulation of Cannabis further confirms the strategic direction of its business model,
  • Company is in an excellent position to commercialize natural health products and drugs post-legalization for both the pet and human markets

OTTAWA, ONTARIO–(Nov. 22, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that the Canadian Government’s Proposed Approach to the Regulation of Cannabis further confirms the strategic direction of its business model, and that the company is in an excellent position to commercialize natural health products and drugs post-legalization for both the pet and human markets.

In the Proposed Approach to the Regulation of Cannabis, Health Canada stated that “[the] Cannabis Act…will maintain a scientific, evidence-based approach for health products with cannabis that are approved with health claims. These products will be subject to the requirements of the FDA and applicable regulations, including requirements for safety, efficacy and quality“. The evidence-based approach applied by Health Canada is consistent with that of Tetra’s business model, and given that the primary goal of regulatory agencies is to protect the health and welfare of consumers, there were no surprises within the recently proposed act. The proposed approach to regulation recommends that cannabis-based health products are still subject to scientific review and must show significant efficacy, meet strict safety requirements and be of sufficient quality in order to gain market approval as a drug or as a natural health product. The burden of evidence and subsequent scientific review process prior to market approval is not required to sell products or medical cannabis through the proposed Cannabis Act, and currently through the Access to Cannabis for Medical Purposes Regulations (ACMPR). However, products made and sold under the current ACMPR/ future Cannabis Act are subject to distinct limitations, such as limits on the allowable cannabinoid concentration, the available dosage and restrictions on health claims, that are not applied to health products which have undergone and received approval by Health Canada.

These regulatory distinctions make Tetra unique from many other businesses within the legalized cannabis industry. Tetra places patients and consumers first in its business model, where providing safe, high quality products that are proven to work is central to the company mission; this will continue to be the company’s vision going forward. Accordingly, the company has initiated multiple clinical research programs aimed at obtaining critical data to address the anticipated pre-marketing requirements for safety and efficacy of their products under development. In parallel, Tetra has also developed the necessary analytical tools to assess and demonstrate the quality of both raw cannabis materials and that of the finished products. Both of these core activities will remain essential parts of the business, as Tetra focuses on becoming a leader in the commercialization of cannabinoid-based health products for humans and pets.

Over the coming months, Tetra will be preparing the implementation of its product launch strategies and preparing for commercialization in accordance with the regulatory framework described in the proposed Cannabis Act.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]
www.tetrabiopharma.com

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma’s $TBP.ca Business Model and Commercialization Strategy In Line with the Canadian Government’s Proposed Approach to the Regulation of Cannabis $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra Bio-Pharma Inc. $TBP.ca Rx Princeps(TM) Now Available for Patients through Licensed Producer Partner Aphria $APH.ca $AERO $CBDS $CGRW $GBLX

Posted by AGORACOM-JC at 8:23 AM on Thursday, November 16th, 2017

Logo tetrabiopharma rgb web

  • Announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc.

OTTAWA, ONTARIO–(Nov. 16, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. (“Aphria”) under Access to Cannabis for Medical Purposes Regulations (ACMPR).

Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now entering this lucrative market and plans on progressively grabbing a significant share of it over the next two years. Mr Fortier, CEO of Tetra, stated last week “We are expecting to generate around $1.5 million in sales, in fiscal 2018 in our initial launch. Through our promotion and education efforts in Quebec, New Brunswick and part of Ontario, we estimate that over eight thousand patients will start using Rx Princeps™ under prescription from their doctors over in the next twelve months.”

Rx Princeps™ is a new option for doctors who want to prescribe medical cannabis. Prescribing Rx Princeps™ with the Rx Princeps™ inhalation device enables their patients to optimize the benefits of medical cannabis through the intake of a fixed dose of product, thereby ensuring consistency of treatment with a standardized high-quality product.

Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada. As a result, Aphria’s products are in line with the strict quality standards Tetra is establishing for the medical community and its patients.

200,000 patients are already registered under the ACMPR program and around 1.5 million adults in Canada suffer from chronic pain and are considered non-responders to opioids; medical cannabis could be a new therapeutic choice for those patients but physicians need bioavailability and safety data to prescribe medical cannabis with confidence. According to Health Canada, less than 3,000 physicians actually prescribe cannabis to their patients. Tetra is committed to provide them rigorous safety and bioavailability data. Tetra has begun educating pain clinics and the medical profession across Canada on Rx Princeps™, including its advantages for patients.

In Quebec, Tetra is working closely with Sante Cannabis in order to educate patients and support them in their medical journey with cannabis. Sante Cannabis is the first cannabinoid clinic and medical marijuana resource centre in Quebec.

About Rx Princeps™:

Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps™ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001. Patients who want to purchase Rx Princeps™ in Canada need a prescription from their physicians and to register with Licensed Producer Aphria.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]
www.tetrabiopharma.com

Tags: , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Inc. $TBP.ca Rx Princeps(TM) Now Available for Patients through Licensed Producer Partner Aphria $APH.ca $AERO $CBDS $CGRW $GBLX

« Older Entries
Newer Entries »